Cargando…
Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers
BACKGROUND: Aberrant activation of the canonical WNT signaling is a feature of colorectal cancer (CRC). Van-Gogh-like 2 (VANGL2) belongs to the non-canonical WNT pathway whose activation inhibits canonical WNT signaling. In this study, we investigated the role of VANGL2 and its epigenetic regulation...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668461/ https://www.ncbi.nlm.nih.gov/pubmed/23579212 http://dx.doi.org/10.1038/bjc.2013.142 |
_version_ | 1782271626795024384 |
---|---|
author | Piazzi, G Selgrad, M Garcia, M Ceccarelli, C Fini, L Bianchi, P Laghi, L D'Angelo, L Paterini, P Malfertheiner, P Chieco, P Boland, C R Bazzoli, F Ricciardiello, L |
author_facet | Piazzi, G Selgrad, M Garcia, M Ceccarelli, C Fini, L Bianchi, P Laghi, L D'Angelo, L Paterini, P Malfertheiner, P Chieco, P Boland, C R Bazzoli, F Ricciardiello, L |
author_sort | Piazzi, G |
collection | PubMed |
description | BACKGROUND: Aberrant activation of the canonical WNT signaling is a feature of colorectal cancer (CRC). Van-Gogh-like 2 (VANGL2) belongs to the non-canonical WNT pathway whose activation inhibits canonical WNT signaling. In this study, we investigated the role of VANGL2 and its epigenetic regulation in CRC. METHODS: Van-Gogh-like 2 expression and promoter methylation after 5-aza-2′-deoxycytidine (5-aza) treatment were evaluated in CRC cells. DNA samples from 418 sporadic CRCs were tested for VANGL2 promoter methylation and microsatellite instability (MSI). Proliferation, colony formation and activation of the WNT pathway were tested in cells after VANGL2 overexpression. RESULTS: Van-Gogh-like 2 mRNA was significantly higher in 5-aza-treated RKO, LOVO and SW48, whereas no differences were found in SW480. Van-Gogh-like 2 was fully methylated in RKO, SW48, HCT116, DLD1 and Caco2; partially methylated in LOVO, LS174T and SW837; and unmethylated in SW480, SW620 and HT29. Higher expression of VANGL2 mRNA was found in the unmethylated cell lines. In CRC specimens (8.93% MSI), methylated VANGL2 was associated with MSI, higher grade, proximal colon location and BRAF mutation. Van-Gogh-like 2 overexpression in SW480 significantly decreased proliferation, colony formation and β-catenin levels. CONCLUSION: Van-Gogh-like 2 is frequently methylated in MSI-CRCs with BRAF mutation and may act as a tumour suppressor gene, counteracting WNT/β-catenin signaling. |
format | Online Article Text |
id | pubmed-3668461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36684612014-04-30 Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers Piazzi, G Selgrad, M Garcia, M Ceccarelli, C Fini, L Bianchi, P Laghi, L D'Angelo, L Paterini, P Malfertheiner, P Chieco, P Boland, C R Bazzoli, F Ricciardiello, L Br J Cancer Genetics and Genomics BACKGROUND: Aberrant activation of the canonical WNT signaling is a feature of colorectal cancer (CRC). Van-Gogh-like 2 (VANGL2) belongs to the non-canonical WNT pathway whose activation inhibits canonical WNT signaling. In this study, we investigated the role of VANGL2 and its epigenetic regulation in CRC. METHODS: Van-Gogh-like 2 expression and promoter methylation after 5-aza-2′-deoxycytidine (5-aza) treatment were evaluated in CRC cells. DNA samples from 418 sporadic CRCs were tested for VANGL2 promoter methylation and microsatellite instability (MSI). Proliferation, colony formation and activation of the WNT pathway were tested in cells after VANGL2 overexpression. RESULTS: Van-Gogh-like 2 mRNA was significantly higher in 5-aza-treated RKO, LOVO and SW48, whereas no differences were found in SW480. Van-Gogh-like 2 was fully methylated in RKO, SW48, HCT116, DLD1 and Caco2; partially methylated in LOVO, LS174T and SW837; and unmethylated in SW480, SW620 and HT29. Higher expression of VANGL2 mRNA was found in the unmethylated cell lines. In CRC specimens (8.93% MSI), methylated VANGL2 was associated with MSI, higher grade, proximal colon location and BRAF mutation. Van-Gogh-like 2 overexpression in SW480 significantly decreased proliferation, colony formation and β-catenin levels. CONCLUSION: Van-Gogh-like 2 is frequently methylated in MSI-CRCs with BRAF mutation and may act as a tumour suppressor gene, counteracting WNT/β-catenin signaling. Nature Publishing Group 2013-04-30 2013-04-11 /pmc/articles/PMC3668461/ /pubmed/23579212 http://dx.doi.org/10.1038/bjc.2013.142 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Genetics and Genomics Piazzi, G Selgrad, M Garcia, M Ceccarelli, C Fini, L Bianchi, P Laghi, L D'Angelo, L Paterini, P Malfertheiner, P Chieco, P Boland, C R Bazzoli, F Ricciardiello, L Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers |
title | Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers |
title_full | Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers |
title_fullStr | Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers |
title_full_unstemmed | Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers |
title_short | Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers |
title_sort | van-gogh-like 2 antagonises the canonical wnt pathway and is methylated in colorectal cancers |
topic | Genetics and Genomics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668461/ https://www.ncbi.nlm.nih.gov/pubmed/23579212 http://dx.doi.org/10.1038/bjc.2013.142 |
work_keys_str_mv | AT piazzig vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT selgradm vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT garciam vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT ceccarellic vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT finil vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT bianchip vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT laghil vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT dangelol vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT paterinip vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT malfertheinerp vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT chiecop vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT bolandcr vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT bazzolif vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers AT ricciardiellol vangoghlike2antagonisesthecanonicalwntpathwayandismethylatedincolorectalcancers |